Target-specific immunoPET Imaging of Digestive System Carcinoma

Launched by RENJI HOSPITAL · Nov 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called target-specific immunoPET/CT to help doctors better see and understand digestive system cancers, including liver, stomach, colon, and pancreatic cancers. The goal is to improve how these cancers are diagnosed by evaluating how well this imaging method works in identifying tumors in the digestive system.

To participate, individuals must be between 18 and 75 years old and have a confirmed or suspected diagnosis of digestive system cancer. They should be able to give consent to join the study. However, people who are pregnant, have severe liver or kidney issues, have had major surgery in the past month, or are allergic to certain imaging agents cannot participate. If you join the trial, you can expect to undergo specific imaging tests to help researchers learn more about this new technique and its effectiveness in diagnosing digestive cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18-75 years old and of either sex；
• • 2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;
• • 3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
• Exclusion Criteria:
• • 1. Pregnancy；
• • 2. Severe hepatic and renal insufficiency;
• • 3. History of serious surgery in the last month;
• • 4. Allergic to antibody or single-domain antibody radiopharmaceuticals.